{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T12:27:42Z","timestamp":1772886462607,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To evaluate acute and late gastrointestinal (GI) and genitourinary (GU) toxicities after moderately hypofractionated (HF) or conventionally fractionated (CF) primary whole-pelvis radiotherapy (WPRT).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Primary prostate-cancer patients treated between 2009 and 2021 with either 60\u202fGy at 3\u202fGy\/fraction to the prostate and 46\u202fGy at 2.3\u202fGy\/fraction to the whole pelvis (HF), or 78\u202fGy at 2\u202fGy\/fraction to the prostate and 50\/50.4\u202fGy at 1.8\u20132\u202fGy\/fraction to the whole pelvis (CF). Acute and late GI and GU toxicities were retrospectively assessed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>106\u00a0patients received HF and 157 received CF, with a\u00a0median follow-up of 12\u00a0and 57\u00a0months. Acute GI toxicity rates in the HF and CF groups were, respectively, grade\u00a02: 46.7% vs. 37.6%, and grade\u00a03: 0% vs. 1.3%, with no significant difference (<jats:italic>p<\/jats:italic>\u202f=\u20090.71). Acute GU toxicity rates were, respectively, grade\u00a02: 20.0% vs. 31.8%, and grade\u00a03: 2.9% vs. 0%, (<jats:italic>p<\/jats:italic>\u202f=\u20090.04). We compared prevalence of late GI and GU toxicities between groups after 3,\u00a012, and 24\u00a0months and did not find any significant differences (respectively, <jats:italic>p<\/jats:italic>\u202f=\u20090.59, 0.22, and 0.71 for GI toxicity; <jats:italic>p<\/jats:italic>\u202f=\u20090.39, 0.58, and 0.90 for GU toxicity).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Moderate HF WPRT was well tolerated during the first 2\u00a0years. Randomized trials are needed to confirm these findings.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00066-023-02104-7","type":"journal-article","created":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T08:02:55Z","timestamp":1687334575000},"page":"188-194","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Assessing the toxicity after moderately hypofractionated prostate and whole pelvis radiotherapy compared to conventional fractionation"],"prefix":"10.1007","volume":"200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5523-8866","authenticated-orcid":false,"given":"Matthias","family":"Moll","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregor","family":"Goldner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,21]]},"reference":[{"issue":"13","key":"2104_CR1","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1200\/JCO.2005.05.2530","volume":"24","author":"STH Peeters","year":"2006","unstructured":"Peeters\u00a0STH et al (2006) Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68\u202fGy of radiotherapy with 78\u202fGy. J\u00a0Clin Oncol 24(13):1990\u20131996. https:\/\/doi.org\/10.1200\/JCO.2005.05.2530","journal-title":"J Clin Oncol"},{"issue":"4","key":"2104_CR2","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.ijrobp.2019.02.045","volume":"104","author":"D Pasalic","year":"2019","unstructured":"Pasalic\u00a0D et al (2019) Dose escalation for prostate adenocarcinoma: a long-term update on the outcomes of a\u00a0phase\u00a03, single institution randomized clinical trial. Int J Radiat Oncol Biol Phys 104(4):790\u2013797. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.02.045","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"2104_CR3","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S1470-2045(07)70143-2","volume":"8","author":"DP Dearnaley","year":"2007","unstructured":"Dearnaley\u00a0DP et al (2007) Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 8(6):475\u2013487. https:\/\/doi.org\/10.1016\/S1470-2045(07)70143-2","journal-title":"Lancet Oncol"},{"issue":"7","key":"2104_CR4","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1200\/JCO.20.02873","volume":"39","author":"LGW Kerkmeijer","year":"2021","unstructured":"Kerkmeijer\u00a0LGW et\u00a0al (2021) Focal boost to the Intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase\u00a0III trial. J\u00a0Clin Oncol 39(7):787\u2013796. https:\/\/doi.org\/10.1200\/JCO.20.02873","journal-title":"J Clin Oncol"},{"issue":"26","key":"2104_CR5","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.1200\/JCO.19.03217","volume":"38","author":"WC Jackson","year":"2020","unstructured":"Jackson\u00a0WC et al (2020) Addition of androgen-deprivation therapy or brachytherapy boost to external beam radiotherapy for localized prostate cancer: a network meta-analysis of randomized trials. J\u00a0Clin Oncol 38(26):3024\u20133031. https:\/\/doi.org\/10.1200\/JCO.19.03217","journal-title":"J Clin Oncol"},{"issue":"3","key":"2104_CR6","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.brachy.2019.01.016","volume":"18","author":"JJ Mohiuddin","year":"2019","unstructured":"Mohiuddin\u00a0JJ, Narayan\u00a0V, Venigalla\u00a0S, Vapiwala\u00a0N (2019) Variations in patterns of concurrent androgen deprivation therapy use based on dose escalation with external beam radiotherapy vs. brachytherapy boost for prostate cancer. Brachytherapy 18(3):322\u2013331. https:\/\/doi.org\/10.1016\/j.brachy.2019.01.016","journal-title":"Brachytherapy"},{"issue":"4","key":"2104_CR7","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.eururo.2018.06.018","volume":"74","author":"A Nabid","year":"2018","unstructured":"Nabid\u00a0A et al (2018) Duration of androgen deprivation therapy in high-risk prostate cancer: a randomized phase\u00a0III trial. Eur Urol 74(4):432\u2013441. https:\/\/doi.org\/10.1016\/j.eururo.2018.06.018","journal-title":"Eur Urol"},{"issue":"24","key":"2104_CR8","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1056\/NEJMoa0810095","volume":"360","author":"M Bolla","year":"2009","unstructured":"Bolla\u00a0M et\u00a0al (2009) Duration of androgen suppression in the treatment of prostate cancer. N\u00a0Engl J Med 360(24):2516\u20132527. https:\/\/doi.org\/10.1056\/NEJMoa0810095","journal-title":"N Engl J Med"},{"issue":"8","key":"2104_CR9","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","volume":"17","author":"D Dearnaley","year":"2016","unstructured":"Dearnaley\u00a0D et al (2016) Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5\u2011year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 17(8):1047\u20131060. https:\/\/doi.org\/10.1016\/S1470-2045(16)30102-4","journal-title":"Lancet Oncol"},{"issue":"17","key":"2104_CR10","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1200\/JCO.2017.72.7016","volume":"35","author":"JB Yu","year":"2017","unstructured":"Yu\u00a0JB (2017) Hypofractionated radiotherapy for prostate cancer: Further evidence to tip the scales. J\u00a0Clin Oncol 35(17):1867\u20131869. https:\/\/doi.org\/10.1200\/JCO.2017.72.7016","journal-title":"J Clin Oncol"},{"issue":"11","key":"2104_CR11","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1016\/S1470-2045(18)30528-X","volume":"19","author":"M Roach","year":"2018","unstructured":"Roach\u00a0M et al (2018) Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG\/RTOG 9413): long-term results of a\u00a0randomised, phase 3 trial. Lancet Oncol 19(11):1504\u20131515. https:\/\/doi.org\/10.1016\/S1470-2045(18)30528-X","journal-title":"Lancet Oncol"},{"issue":"4","key":"2104_CR12","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.ijrobp.2016.06.2455","volume":"96","author":"P Pommier","year":"2016","unstructured":"Pommier\u00a0P et al (2016) Is there a\u00a0role for pelvic irradiation in localized prostate adenocarcinoma? Update of the long-term survival results of the GETUG-01 randomized study. Int J Radiat Oncol Biol Phys 96(4):759\u2013769. https:\/\/doi.org\/10.1016\/j.ijrobp.2016.06.2455","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"2104_CR13","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1378\/chest.85.4.457","volume":"40","author":"SO Asbell","year":"1998","unstructured":"Asbell\u00a0SO, Martz\u00a0K, Pilepich\u00a0MV (1998) Impact of surgical staging in evaluating the radiotherapeutic outcome in RTOG #77-06, A phase III study for T1BN0M0 (A2) and T2N0M0 (B) prostate carcinoma. Int J Radiat Oncol Biol Phys 40(4):769\u2013782. https:\/\/doi.org\/10.1378\/chest.85.4.457","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"2104_CR14","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1200\/JCO.20.03282","volume":"39","author":"V Murthy","year":"2021","unstructured":"Murthy\u00a0V et al (2021) Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase\u00a0III randomized controlled trial. J\u00a0Clin Oncol 39(11):1234\u20131242. https:\/\/doi.org\/10.1200\/JCO.20.03282","journal-title":"J Clin Oncol"},{"key":"2104_CR15","unstructured":"Schaeffer EM et\u00a0al (2022) NCCN guidelines version 4.2022 prostate cancer. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf. Accessed 8 Aug 2022"},{"key":"2104_CR16","unstructured":"NICE guideline [NG131], \u201cOverview | Prostate cancer: diagnosis and management | Guidance | NICE,\u201d Nice, no. May 2019, p.\u00a06, 2019, [Online]. Available: https:\/\/www.nice.org.uk\/guidance\/ng131, accessed 18 Aug 2021"},{"issue":"34","key":"2104_CR17","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.1200\/JCO.18.01097","volume":"36","author":"SC Morgan","year":"2018","unstructured":"Morgan\u00a0SC et al (2018) Hypofractionated radiation therapy for localized prostate cancer: an ASTRO, ASCO, and AUA evidence-based guideline. J\u00a0Clin Oncol 36(34):3411\u20133430. https:\/\/doi.org\/10.1200\/JCO.18.01097","journal-title":"J Clin Oncol"},{"issue":"1","key":"2104_CR18","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ijrobp.2020.08.034","volume":"109","author":"WA Hall","year":"2021","unstructured":"Hall\u00a0WA et\u00a0al (2021) NRG oncology updated international consensus atlas on pelvic lymph node volumes for intact and postoperative prostate cancer. Int J Radiat Oncol Biol Phys 109(1):174\u2013185. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.08.034","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2104_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2022.04.008","author":"GA Viani","year":"2022","unstructured":"Viani\u00a0GA, Gouveia\u00a0AG, Moraes\u00a0FY, Cury\u00a0FL (2022) Meta-analysis of elective pelvic nodal irradiation using moderate hypofractionation for high-risk prostate cancer\u2019 (MENHYP-ENI). Int J Radiat Oncol. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.04.008","journal-title":"Int J Radiat Oncol"},{"issue":"6","key":"2104_CR20","doi-asserted-by":"publisher","first-page":"e514","DOI":"10.1016\/j.prro.2020.06.012","volume":"10","author":"S Faria","year":"2020","unstructured":"Faria\u00a0S et al (2020) Long-term results of moderate hypofractionation to prostate and pelvic nodes plus androgen suppression in high-risk prostate cancer. Pract Radiat Oncol 10(6):e514\u2013e520. https:\/\/doi.org\/10.1016\/j.prro.2020.06.012","journal-title":"Pract Radiat Oncol"},{"issue":"1","key":"2104_CR21","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1016\/j.clon.2021.08.010","volume":"34","author":"S Maulik","year":"2022","unstructured":"Maulik\u00a0S, Arunsingh\u00a0M, Arun\u00a0B, Prasath\u00a0S, Mallick\u00a0I (2022) Moderately hypofractionated radiotherapy and androgen deprivation therapy for high-risk localised prostate cancer: predictors of long-term biochemical control and toxicity. Clin Oncol 34(1):e52\u2013e60. https:\/\/doi.org\/10.1016\/j.clon.2021.08.010","journal-title":"Clin Oncol"},{"issue":"3","key":"2104_CR22","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.ijrobp.2006.05.074","volume":"66","author":"M Roach","year":"2006","unstructured":"Roach\u00a0M et al (2006) Whole-pelvis, \u2018mini-pelvis,\u2019 or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Radiat Oncol Biol Phys 66(3):647\u2013653. https:\/\/doi.org\/10.1016\/j.ijrobp.2006.05.074","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2104_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jicru_ndq002","volume":"15","author":"H\u2011G Menzel","year":"2010","unstructured":"Menzel H\u2011G (2010) ICRU report 83 prescribing, recording, and reporting photon-beam intensity-modulated radiation therapy (IMRT). Journal of the ICRU 15:1\u20132. https:\/\/doi.org\/10.1093\/jicru_ndq002","journal-title":"Journal of the ICRU"},{"issue":"1","key":"2104_CR24","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0360-3016(01)01821-1","volume":"52","author":"S Wachter","year":"2002","unstructured":"Wachter\u00a0S et al (2002) The influence of a\u00a0rectal balloon tube as internal immobilization device on variations of volumes and dose-volume histograms during treatment course of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 52(1):91\u2013100. https:\/\/doi.org\/10.1016\/S0360-3016(01)01821-1","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2104_CR25","unstructured":"Deutsche Gesellschaft f\u00fcr Urologie, \u201cLeitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Prostatakarzinom, Langversion 6.0, 2021, AWMF Registernummer: 043\/022OL,\u201d 2021, [Online]. Available: https:\/\/www.leitlinienprogramm-onkologie.de\/mwg-internal\/de5fs23hu73ds\/progress?id=6EduY9K1iK09VZIlf8dOvGrff8piCbbjGVH9Qi0SqOo, (accessed 16.06.2021, 8:15 am)"},{"issue":"5","key":"2104_CR26","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","volume":"31","author":"JD Cox","year":"1995","unstructured":"Cox\u00a0JD, Stetz\u00a0J, Pajak\u00a0TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol 31(5):1341\u20131346. https:\/\/doi.org\/10.1016\/0360-3016(95)00060-C","journal-title":"Int J Radiat Oncol"},{"key":"2104_CR27","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.radonc.2019.12.006","volume":"145","author":"V Murthy","year":"2020","unstructured":"Murthy\u00a0V et al (2020) Late toxicity and quality of life with prostate only or whole pelvic radiation therapy in high risk prostate cancer (POP-RT): A randomised trial. Radiother Oncol 145:71\u201380. https:\/\/doi.org\/10.1016\/j.radonc.2019.12.006","journal-title":"Radiother Oncol"},{"issue":"1","key":"2104_CR28","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1470-2045(11)70293-5","volume":"13","author":"D Dearnaley","year":"2012","unstructured":"Dearnaley\u00a0D et al (2012) Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: Preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol 13(1):43\u201354. https:\/\/doi.org\/10.1016\/S1470-2045(11)70293-5","journal-title":"Lancet Oncol"},{"issue":"1","key":"2104_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13014-021-01976-2","volume":"17","author":"C Phuong","year":"2022","unstructured":"Phuong\u00a0C et\u00a0al (2022) Safety of accelerated hypofractionated whole pelvis radiation therapy prior to high dose rate brachytherapy or stereotactic body radiation therapy prostate boost. Radiat Oncol 17(1):1\u20137. https:\/\/doi.org\/10.1186\/s13014-021-01976-2","journal-title":"Radiat Oncol"},{"issue":"5","key":"2104_CR30","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1056\/NEJM199707313370502","volume":"337","author":"M Bolla","year":"1997","unstructured":"Bolla\u00a0M et\u00a0al (1997) Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N\u00a0Engl J Med 337(5):295\u2013300","journal-title":"N Engl J Med"},{"key":"2104_CR31","doi-asserted-by":"publisher","DOI":"10.2478\/raon-2023-0004","author":"M Moll","year":"2023","unstructured":"Moll\u00a0M, Wei\u00df\u00a0M, Stanisav\u00a0V, Zaharie\u00a0A, Goldner\u00a0G (2023) Effects of gold fiducial marker implantation on tumor control and toxicity in external beam radiotherapy of prostate cancer. Radiol Oncol. https:\/\/doi.org\/10.2478\/raon-2023-0004","journal-title":"Radiol Oncol"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-023-02104-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-023-02104-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-023-02104-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T16:03:28Z","timestamp":1708358608000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-023-02104-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,21]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["2104"],"URL":"https:\/\/doi.org\/10.1007\/s00066-023-02104-7","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,21]]},"assertion":[{"value":"12 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.\u00a0Moll and G.\u00a0Goldner declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}